The first of five early stage clinical trials to test the safety and ability of an investigational Zika vaccine candidate called the Zika Purified Inactivated Virus (ZPIV) vaccine to generate an immune system response has begun at the Walter Reed Army Institute of Research (WRAIR) Clinical Trial Center in Silver Spring, Maryland. Scientists with WRAIR, part of the U.S. Department of Defense (DoD), developed the vaccine. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is co-funding the Phase 1 clinical trial with WRAIR, serving as the regulatory sponsor and providing other support

Related posts:

  1. Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins...
  2. Medicare Card, NIH begins testing investigational Zika vaccine in humans Medicare Card, NIH begins testing investigational Zika vaccine in humans...
  3. Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year...
  4. Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial...
  5. Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
  6. Medicare Card, NIH launches trial of investigational genital herpes vaccine Medicare Card, NIH launches trial of investigational genital herpes vaccine...
  7. Medicare Card, Large-scale HIV vaccine trial to launch in South Africa Medicare Card, Large-scale HIV vaccine trial to launch in South Africa...
  8. Medicare Card, NIH launches early-stage yellow fever vaccine trial Yellow fever virus is found in tropical and subtropical, and caused an estimated 29,000 to 60,000 deaths in 2013. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. The Phase 1 […]...
  9. Possible clues found to why HIV vaccine showed modest protection Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial, those who produced relatively high levels of a […]...
  10. Medicare Card, Experimental chikungunya vaccine induces robust antibody response An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results are reported in the current issue of […]...
  11. Priming with DNA vaccine makes avian flu vaccine work better The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), […]...
  12. Medicare, Funded HIV clinical research sites to join pediatric tuberculosis vaccine study Several U.S. government-funded HIV/AIDS clinical research sites in Africa will join other collaborators in an ongoing clinical trial testing an investigational tuberculosis (TB) vaccine in infants at risk for TB infection. “We are pleased to be able to tap into our existing HIV/AIDS clinical research infrastructure to help test promising investigational vaccines against TB,” said […]...
  13. NIH Scientists Advance Universal Flu Vaccine A universal influenza vaccine — so-called because it could potentially provide protection from all flu strains for decades — may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health....
  14. HIV Vaccine Awareness Day May 18, 2011 Thirty years since the first report of the disease we now know as AIDS, scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, continue advancing toward our goal of a vaccine to prevent HIV infection. I am optimistic that we will succeed....
  15. Medicare NIH funds four clinical trials to fight antimicrobial resistance The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new contracts for large-scale clinical trials that address the problem of antimicrobial resistance. Over the next five to six years, these new clinical trials will evaluate treatment alternatives for diseases for which antibiotics are prescribed most […]...